Evidence map›Paper›PMID 34621884›Full record

ArticleWorld journal of clinical cases2021

Non-small-cell lung cancer with epidermal growth factor receptor L861Q-L833F compound mutation benefits from both afatinib and osimertinib: A case report.

Yao Zhang, Ji-Qiao Shen, Lin Shao, Yan Chen, Lei Lei, Jia-Lei Wang

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of clinical cases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Yao ZhangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Ji-Qiao ShenDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Lin ShaoBurning Rock Biotech, Guangzhou 510300, Guangdong Province, China.
Yan ChenBurning Rock Biotech, Guangzhou 510300, Guangdong Province, China.
Lei LeiBurning Rock Biotech, Guangzhou 510300, Guangdong Province, China.
Jia-Lei WangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Burning Rock Biotech (China) · CNFudan University · CNShanghai Medical College of Fudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEpidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been adopted as the standard of care for non-small cell lung cancer (NSCLC) patients harboring CASE SUMMARY: Herein, we report a 55-year-old male patient with stage IV NSCLC harboring a rare

conclusionOur case revealed that both afatinib and the osimertinib + bevacizumab combination demonstrated clinical efficacy in NSCLC harboring an

Indexed as

AfatinibCase reportEpidermal growth factor receptorL861Q-L833FNon-small cell lung cancerOsimertinib

Identifiers

PMID34621884
PMCPMC8462190
OpenAlexW3200640153

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.